Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Globe Newswire•19/10/2026•08:00 ET
0
Key Highlights
- ➤IMPACT Phase 2b showed concurrent reductions in liver stiffness and ELF score at 48 weeks
- ➤Pemvidutide reduced liver fat and ALT versus placebo in MASH patients
- ➤Gastrointestinal adverse events were mild to moderate, with no severe events reported
- ➤Preclinical hamster data showed significant reduction in mean alcohol intake
- ➤PERFORMA Phase 3 trial is actively enrolling patients with MASH
Expert Statements
John J. Suschak, Presenter of the pemvidutide alcohol-intake study
“Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model”
Dr. Naim Alkhouri, Presenter of the IMPACT Phase 2b MASH study
“Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis”
Dr. Mazen Noureddin, Presenter of the IMPACT Phase 2b gastrointestinal tolerability study
“Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial”
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability
Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide
Get started
Create a free account to read the full story.